TT-232
Based on 1 Customer Validation
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.72%
- CAS No.: 147159-51-1
- Formule: C45H58N10O9S2
- Masse moléculaire:947.13
-
Stockage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
SSTR1 |
SSTR4 |
TT-232 (10 μg/mL, 48 h) induces apoptosis in human colon (HT-29 and SW620), pancreatic (818), leukemia (K-562), melanoma (WM 938/B, M-1 and EP) and lymphoma (HT-58) tumor cell lines[1].
TT-232 (20-30 μg/mL, 24 h) shows antiproliferative effect on various human tumor cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7, PC-3, P818, K-562, 4-1ST, ect.
-
Concentration:20-30 μg/mL
-
Incubation Time:24 h
-
Result:Inhibited cell proliferation by 87%, 90%, 98%, 95%, respectively.
TT-232 (0.6 or 15 μg/kg s.c or i.p.) shows antitumor effect on P-388 rodent lymphocytic leukemia tumor mice[3].
TT-232 (7.5-20 μg/kg, i.v.) inhibits Carrageenin-induced paw oedema in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice transplanted with Colon 26 cell [2].
-
Dosage:15, 150, 750 μg/kg/day
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Reached 70% tumor inhibition at 750 μg/kg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 147159-51-1
-
Appearance Solid
-
Masse moléculaire 947.13
-
Formule C45H58N10O9S2
-
Color White to off-white
-
Synonyms
CAP-232; TLN-232
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvant et solubilité
H2O : < 0.1 mg/mL (insoluble)
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14(8):585-8. [Content Brief]
[2]. Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8. [Content Brief]
[3]. Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. [Content Brief]
[4]. Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):142-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TT-232 Related Classifications
HY-105172 Related Classifications
Powered by Bioz